Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.

Compte M, Harwood SL, Muñoz IG, Navarro R, Zonca M, Perez-Chacon G, Erce-Llamazares A, Merino N, Tapia-Galisteo A, Cuesta AM, Mikkelsen K, Caleiras E, Nuñez-Prado N, Aznar MA, Lykkemark S, Martínez-Torrecuadrada J, Melero I, Blanco FJ, Bernardino de la Serna J, Zapata JM, Sanz L, Alvarez-Vallina L.

Nat Commun. 2018 Nov 15;9(1):4809. doi: 10.1038/s41467-018-07195-w.

2.

Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.

Mølgaard K, Harwood SL, Compte M, Merino N, Bonet J, Alvarez-Cienfuegos A, Mikkelsen K, Nuñez-Prado N, Alvarez-Mendez A, Sanz L, Blanco FJ, Alvarez-Vallina L.

Cancer Immunol Immunother. 2018 Aug;67(8):1251-1260. doi: 10.1007/s00262-018-2181-5. Epub 2018 Jun 4.

PMID:
29869168
3.

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.

Harwood SL, Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Hernández-Pérez S, Merino N, Bonet J, Navarro R, Van Bergen En Henegouwen PMP, Lykkemark S, Mikkelsen K, Mølgaard K, Jabs F, Sanz L, Blanco FJ, Roda-Navarro P, Alvarez-Vallina L.

Oncoimmunology. 2017 Sep 27;7(1):e1377874. doi: 10.1080/2162402X.2017.1377874. eCollection 2017.

4.

Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.

Mølgaard K, Compte M, Nuñez-Prado N, Harwood SL, Sanz L, Alvarez-Vallina L.

Gene Ther. 2017 Apr;24(4):208-214. doi: 10.1038/gt.2017.3. Epub 2017 Jan 11.

5.

Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains.

Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Cuesta AM, Blanco-Toribio A, Harwood SL, Villate M, Merino N, Bonet J, Navarro R, Muñoz-Briones C, Sørensen KM, Mølgaard K, Oliva B, Sanz L, Blanco FJ, Alvarez-Vallina L.

Sci Rep. 2016 Jun 27;6:28643. doi: 10.1038/srep28643.

6.

Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?

Alonso-Camino V, Harwood SL, Álvarez-Méndez A, Alvarez-Vallina L.

Biochem Soc Trans. 2016 Apr 15;44(2):406-11. doi: 10.1042/BST20150286. Review.

PMID:
27068947
7.

The coming of age of engineered multivalent antibodies.

Nuñez-Prado N, Compte M, Harwood S, Álvarez-Méndez A, Lykkemark S, Sanz L, Álvarez-Vallina L.

Drug Discov Today. 2015 May;20(5):588-94. doi: 10.1016/j.drudis.2015.02.013. Epub 2015 Mar 7. Review.

PMID:
25757598
8.

Supplemental Content

Loading ...
Support Center